Introduction {#s1}
============

Tuberculosis (TB) affected an estimated 10.4 million people in 2016, with 1.3 million attributable deaths in those without HIV and a further 374 000 deaths in HIV co-infected persons \[[@C1]\]. Just 57% of pulmonary TB cases reported to the World Health Organization (WHO) were bacteriologically confirmed. Chronic pulmonary aspergillosis (CPA) both complicates and mimics treated pulmonary TB \[[@C2], [@C3]\]. The prevalence of CPA in patients with treated TB and the contribution of misdiagnosed CPA to TB prevalence estimates are unclear.

The European Respiratory Society (ERS) published the first guidelines on CPA diagnosis and management in 2016 \[[@C4]\]. Chronic cavitary pulmonary aspergillosis (CCPA) is the most common form of CPA \[[@C5], [@C6]\]. It presents with progressive cavitation and symptoms including weight loss, fatigue, cough, breathlessness, chest discomfort and haemoptysis. The 5-year mortality of CCPA is 38--80% \[[@C3], [@C7]\]. However, surgery is curative in selected patients with localised disease and has been safely delivered in resource-poor settings \[[@C8]--[@C11]\]. Treatment with oral azole drugs can prevent clinical and radiological progression \[[@C12]--[@C14]\]. Chronic fibrosing pulmonary aspergillosis (CFPA) complicates untreated CCPA, with destruction of the lung \[[@C15]\]. [Figure 1](#F1){ref-type="fig"} illustrates the subtypes of CPA.

![Venn diagram showing subtypes of chronic pulmonary aspergillosis (CPA). CCPA: chronic cavitary pulmonary aspergillosis; CFPA: chronic fibrosing pulmonary aspergillosis; AN: *Aspergillus* nodules; SA: simple aspergilloma. All patients have CPA. The size of each group represents the approximate estimated prevalence of each condition. Patients with subacute invasive pulmonary aspergillosis do not have CPA and are not included.](ERJ-01184-2018.01){#F1}

Sputum culture for *Aspergillus* is often negative in CPA \[[@C2]\]. Measurement of *Aspergillus*-specific IgG is central to CPA diagnosis \[[@C4], [@C16]\], but until recently had been inadequately validated for use in this context \[[@C17]\]. Both tests are infrequently available in areas of high TB prevalence \[[@C18]\].

Our recent studies demonstrate that Siemens Immulite *Aspergillus*-specific IgG is the best performing commercial assay for CPA diagnosis \[[@C5]\]. It has a sensitivity of 93.4% for UK CPA cases and specificity of 98.7% against healthy controls or 97.9% against Ugandan controls with treated pulmonary TB at a cut-off of 20 mg·L^−1^, regardless of HIV status \[[@C19]\].

The global prevalence of CPA secondary to TB has been estimated at 1.2 million cases \[[@C20]\]. CPA has a global distribution, including over 200 reported cases in Africa \[[@C2], [@C3], [@C8], [@C11], [@C12], [@C21]--[@C26]\]. Prevalence estimates are based on the results of a 1968--1970 survey describing aspergilloma in 20% of 544 British patients with residual lung cavities after TB treatment \[[@C27]\]. That study was performed prior to computed tomography (CT) scanning and the HIV pandemic. Subsequent studies have demonstrated that aspergilloma is only present in a third of CPA cases \[[@C2]\].

We aimed to undertake the first accurate measurement of CPA prevalence. We conducted a community-based, cross-sectional prospective survey with systematic CT scanning of the thorax in an area of high TB prevalence. The prevalence of CPA in patients with and without HIV infection and chest radiography cavitation was compared, and the annual rate of CPA development between two surveys 2 years apart described.

Current CPA diagnostic criteria are arbitrary and based on expert opinion \[[@C4]\]. We aimed to conduct the first assessment of associations between raised *Aspergillus*-specific IgG and individual clinical or radiological features.

Pulmonary TB mostly occurs in resource-poor settings, where access to CT scanning of the thorax and *Aspergillus*-specific IgG testing is limited \[[@C18], [@C20]\]. We describe the accuracy of CPA diagnosis by chest radiography and clinical assessment, with or without serology, in comparison to CT-confirmed disease.

Methods {#s2}
=======

Adults aged ≥16 years, who were in the final month of pulmonary TB treatment or completed treatment in 2005 or later, were recruited in Gulu (Uganda) from October 2012 to January 2013. Patients were recruited from Gulu Regional Referral Hospital TB and HIV clinics or by Gulu District Health Office staff. Eligible patients had smear-positive TB or complete resolution of symptoms on therapy. We aimed to recruit 50% of patients with HIV co-infection at the time of TB treatment. Patients with no recorded HIV status who declined testing were ineligible.

Patients underwent structured clinical assessment. "Severe dyspnoea" represents a Medical Research Council dyspnoea score of 4 or 5. Chest radiography was performed at St Mary\'s Hospital at Lacor, Gulu. Serum was stored at −80°C at the Joint Clinical and Research Centre (JCRC) in Gulu. Immulite 2000 *Aspergillus fumigatus*-specific IgG testing (Siemens, Berlin, Germany) was performed at Christie Hospital (Manchester, UK) in July 2014. Raised levels are ≥20 mg·L^−1^. CD4 testing was performed by FACSCalibur flow cytometry (Becton Dickinson, Franklin Lakes, NJ, USA) at the JCRC, if no recent result was documented (\<6 months).

Patients were traced and reassessed (resurvey) between October 2014 and January 2015, with repeat chest radiography and *Aspergillus*-specific IgG. GeneXpert IV *Mycobacterium tuberculosis* nucleic acid amplification testing (Cepheid, Sunnyvale, CA, USA) was performed at Gulu Regional Referral Hospital for all patients who could provide a sputum sample. CT scanning of the thorax was performed using a Dual Slice scanner (GE, Boston, MA, USA) at the Kampala Imaging Centre (Uganda) on those with *Aspergillus*-specific IgG \>10 mg·L^−1^ or report of a fungal ball on chest radiography by any radiologist in the initial survey. Digital CT images were reported using Osirix X software (Pixmeo, Bernex, Switzerland). Two radiologists, blinded to clinical and serological findings, provided radiological reports. The senior respiratory radiologist (R.S.) at the UK National Aspergillosis Centre (Manchester, UK) provided a decisive report where initial reports differed.

In the first survey, probable CCPA was diagnosed when three criteria were met: 1) cough or haemoptysis for ≥1 month, 2) cavitation or a fungal ball on chest radiography and 3) raised *Aspergillus*-specific IgG. Probable simple aspergilloma was diagnosed in patients with a fungal ball on chest radiography and raised *Aspergillus*-specific IgG, but no chronic cough or haemoptysis. All "probable CPA" is the combination of patients with probable CCPA or probable simple aspergilloma.

CPA was definitively diagnosed after the resurvey. A modified version of the D[enning]{.smallcaps} *et al*. \[[@C21]\] 2003 criteria was used. CCPA cases had all of: 1) cough or haemoptysis for ≥1 month, 2) raised *Aspergillus*-specific IgG, 3) absence of positive GeneXpert test for *M. tuberculosis* and 4) either paracavitary fibrosis or a fungal ball on CT of the thorax or progressive cavitation (either new cavitation or deterioration of pre-existing cavitation) on serial chest radiographs.

CFPA was diagnosed in patients with clinical and serological features of CCPA and complete destruction of at least two lobes of a lung on CT of the thorax. Simple aspergilloma was diagnosed in patients with a fungal ball on CT of the thorax and raised *Aspergillus*-specific IgG, but no cough or haemoptysis. The combined totals of CCPA, CFPA and simple aspergilloma are presented as "all CPA". A seronegative fungal ball was reported in patients with a fungal ball on CT of the thorax, but normal *Aspergillus-*specific IgG.

New CPA, developing during the 2-year follow-up period, was diagnosed in those who had normal *Aspergillus*-specific IgG in the initial survey, but CPA on resurvey, on the basis of resurvey criteria where CT scanning was performed and original survey criteria where it was not. Those patients diagnosed with CPA in the absence of CT of the thorax were reported as "probable CPA" in the final prevalence results.

Ethical approval {#s2a}
----------------

Ethical approval was granted by The University of Manchester Research Ethics Committee (7/6/12-11424), Gulu University Faculty of Medicine Institutional Review Board (GU/IRC/04/07/12), and the Uganda National Council for Science and Technology (HS 1253).

Statistical analysis {#s2b}
--------------------

Statistical analysis was performed using SPSS version 20 (IBM, Armonk, NY, USA). The study was designed to measure the prevalence of CPA with an accuracy of ±2.3% based on a predicted prevalence of 6%. It had 80% power to detect an absolute difference of 9% in CPA prevalence between HIV-positive and HIV-negative groups with 5% significance. Frequencies of categorical variables were compared by Fisher\'s exact test throughout, unless otherwise stated. Mean results were compared by the t-test and median results by the Mann--Whitney U-test. 95% confidence intervals for disease prevalence were calculated by the Jeffreys method.

In additional *post hoc* analyses we assessed associations between potential clinical and environmental risk factors and CPA diagnosis or raised *Aspergillus-*specific IgG. We also assessed associations between individual symptoms and radiological findings and CPA diagnosis or raised *Aspergillus-*specific IgG. Odds ratios for associations between clinical or radiological features and CPA were calculated by bimodal regression analysis.

We calculated the sensitivity, specificity, and positive and negative predictive values of various combinations of symptoms, radiological results and *Aspergillus-*specific IgG testing in relation to final CPA diagnosis after CT of the thorax. The accuracy of chest radiography for diagnosis of CT-proven pathology was described in the same manner.

Results {#s3}
=======

Patient characteristics and initial survey results are shown in [table 1](#TB1){ref-type="table"}. Median time from completion of TB treatment to recruitment was 29 months. Low CD4 counts were uncommon in HIV-positive patients. Cough and cavitation on chest radiography were more common in HIV-negative patients in the initial survey. 11 (2.8%) patients met the criteria for probable CPA, comprising nine (2.3%) with CCPA and two (0.5%) with simple aspergilloma.

###### 

Patient characteristics and initial survey results (2012)

                                                                         **All patients**   **Resurveyed patients**   **Lost to follow-up or died**   **p-value**   **HIV-positive**   **HIV-negative**   **p-value**
  --------------------------------------------------------------------- ------------------ ------------------------- ------------------------------- ------------- ------------------ ------------------ -------------
  **Subjects**                                                                 398                    284                          114                                    199                199         
  **HIV infection**                                                         199 (50.0)            135 (47.5)                    64 (56.1)                0.149                                           
  **CD4 count \<100 cells·µL^−1^**                                           8 (2.0)                3 (1.1)                      5 (4.4)                 0.046          8 (4.0)               0              0.007
  **Female**                                                                155 (38.9)            100 (35.2)                    55 (48.2)                0.017         98 (49.2)          57 (28.6)         \<0.001
  **Positive sputum smear at TB diagnosis**                                 303 (76.1)            224 (78.9)                    79 (69.3)                0.051         134 (67.3)         169 (84.9)        \<0.001
  **On TB treatment**                                                        10 (2.5)               6 (2.1)                      4 (3.5)               0.386^¶^         10 (5.0)              0           \<0.001^¶^
  **\<1 year from TB treatment**                                            86 (21.6)              56 (19.7)                    30 (26.3)                              36 (18.1)          50 (25.1)      
  **1--3 years from TB treatment**                                          141 (35.4)            105 (37.0)                    36 (31.6)                              60 (30.2)          81 (40.7)      
  **\>3 years from TB treatment**                                           160 (40.2)            116 (40.8)                    44 (38.6)                              93 (46.7)          67 (33.7)      
  **Traditional "grass-thatch" home**                                       371 (93.2)            269 (94.7)                   102 (89.5)                0.077          183 (92)          188 (94.5)         0.426
  **Dampness reported in home**                                             119 (29.9)             77 (27.1)                    42 (36.8)                0.069         62 (31.2)          57 (28.6)          0.662
  **Subsistence farmer**                                                    373 (93.7)            269 (94.7)                   104 (91.2)                0.252         180 (90.5)          193 (97)          0.012
  **Frequently cooks on open charcoal stove**                               81 (20.4)              57 (20.1)                    24 (21.1)                0.891         45 (22.6)          36 (18.1)          0.319
  **Smokes tobacco**                                                         39 (9.8)              30 (10.6)                     9 (7.9)                 0.462          13 (6.5)          26 (13.1)          0.042
  **Age (mean (range)) years**                                             42 (16--83)                42                           41                    0.332        40 (16--73)        44 (16--83)        \<0.001
  **CD4 count in HIV-positive persons (median (range)) cells·µL^−1^**     424 (14--1400)        424 (59--1400)                439 (14--869)              0.664                                           
  **Cough^\#^**                                                             130 (32.7)             92 (32.4)                    38 (33.3)                0.906         51 (25.6)          79 (39.7)          0.004
  **Haemoptysis^\#^**                                                        14 (3.5)              11 (3.9)                      3 (2.6)                 0.765          5 (2.5)            9 (4.5)           0.415
  **Fatigue^\#^**                                                           191 (48.0)            138 (48.6)                    53 (46.5)                0.740         96 (48.2)          95 (47.7)            1
  **Fevers^\#^**                                                            99 (24.9)              74 (26.1)                    25 (21.9)                0.442         50 (25.1)          49 (24.6)            1
  **Severe dyspnoea^\#^**                                                   90 (22.6)              57 (20.1)                    33 (28.9)                0.064         43 (21.6)          47 (23.6)          0.719
  **Night sweats^\#^**                                                      131 (32.9)             98 (34.5)                    33 (28.9)                0.345         54 (27.1)          77 (38.7)          0.019
  **Chest pain^\#^**                                                        214 (53.8)            163 (57.4)                    51 (44.7)                0.026         99 (49.7)          115 (57.8)         0.131
  **Cavitation**                                                            65 (16.3)              46 (16.2)                    19 (16.7)                0.882         24 (12.1)          41 (20.6)          0.029
  **Paracavitary fibrosis**                                                  34 (8.5)              24 (8.5)                     10 (8.8)                   1            14 (7.0)          20 (10.1)          0.370
  **Pleural thickening**                                                    58 (14.6)              44 (15.5)                    14 (12.3)                0.530         23 (11.6)          35 (17.6)          0.118
  **Fungal ball**                                                            15 (3.8)               9 (3.2)                      6 (5.3)                 0.383          5 (2.5)            10 (5.0)          0.292
  ***Aspergillus* IgG \>20 mg·L^−1^**                                        21 (5.3)              15 (5.3)                      6 (5.3)                   1            7 (3.5)            14 (7.0)          0.177

Data are presented as n or n (%), unless otherwise stated. TB: tuberculosis. ^\#^: present for ≥1 month; ^¶^: two-sided Chi-squared test. p-values calculated by Fisher\'s exact test, except where indicated. Mean results compared by the t-test and median results by the Mann--Whitney U-test. p\<0.05 considered significant.

At the 2-year follow-up, 285 (71.6%) patients were resurveyed and 19 (4.8%) were confirmed to have died between surveys. 94 (23.6%) could not be traced. Rates of loss to follow-up were similar in those with or without probable CPA (27.3% *versus* 24.0%; p=0.731). No patient with probable CPA died between surveys.

Results for resurvey patients are compared in [table 2](#TB2){ref-type="table"}. While overall symptom frequency fell between surveys, frequency of haemoptysis and raised *Aspergillus*-specific IgG increased. Radiological findings consistent with CPA and elevated *Aspergillus*-specific IgG were more common in males (p=0.012--0.041), but symptoms consistent with CPA were not (p=0.270--0.830) ([supplementary table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01184-2018.figures-only#fig-data-supplementary-materials)).

###### 

Results for resurvey patients

                                                             **Initial survey**   **Resurvey**   **p-value**   **Resurvey HIV-positive**   **Resurvey HIV-negative**   **p-value**
  --------------------------------------------------------- -------------------- -------------- ------------- --------------------------- --------------------------- -------------
  **Subjects**                                                      284               284                                 135                         150             
  **Cough^\#^**                                                  92 (32.4)         94 (33.0)        0.929              34 (25.2)                   60 (40.0)              0.008
  **Haemoptysis^\#^**                                             11 (3.9)          21 (7.4)         0.1               11 (8.1)                    10 (6.7)               0.657
  **Fatigue^\#^**                                                138 (48.6)        89 (31.2)       \<0.001             40 (29.6)                   49 (32.7)              0.610
  **Fevers^\#^**                                                 74 (26.1)          26 (9.1)       \<0.001             12 (8.9)                    14 (9.3)                 1
  **Severe dyspnoea^\#^**                                        57 (20.1)          3 (1.1)        \<0.001              3 (2.2)                        0                  0.105
  **Night sweats^\#^**                                           98 (34.5)         51 (17.9)       \<0.001             22 (16.3)                   29 (19.3)              0.539
  **Chest pain^\#^**                                             163 (57.4)        76 (26.7)       \<0.001             31 (23.0)                   45 (30.0)              0.227
  **Cavitation**                                                 46 (16.2)         50 (17.5)        0.737              20 (14.8)                   30 (20.0)              0.277
  **New cavitation**                                                                4 (1.4)                             3 (2.2)                     1 (0.7)               0.346
  **Deterioration of pre-existing cavitation**                                      3 (1.1)                             3 (2.2)                        0                  0.104
  **All progressive cavitation**                                                    7 (2.5)                             6 (4.4)                     1 (0.7)               0.055
  **Paracavitary fibrosis**                                       24 (8.5)         36 (12.6)        0.133              15 (11.1)                   21 (14.0)              0.481
  **New paracavitary fibrosis**                                                     12 (4.2)                            4 (3.0)                     8 (5.3)               0.387
  **Deterioration of pre-existing paracavitary fibrosis**                           6 (2.1)                             3 (2.2)                     3 (2.0)                 1
  **All progressive paracavitary fibrosis**                                         18 (6.3)                            7 (5.2)                    11 (7.3)               0.627
  **Pleural thickening**                                         44 (15.5)         50 (17.5)        0.573              20 (14.8)                   30 (20.0)              0.277
  **New pleural thickening**                                                        6 (2.1)                             3 (2.2)                     3 (2.0)                 1
  **Deterioration of pre-existing pleural thickening**                              10 (3.5)                            3 (2.2)                     7 (4.7)               0.343
  **All progressive pleural thickening**                                            16 (5.6)                            6 (4.4)                    10 (6.7)               0.453
  **Fungal ball**                                                 9 (3.2)           13 (4.6)        0.515               4 (3.0)                     9 (6.0)               0.265
  **New fungal ball**                                                               4 (1.4)                             2 (1.5)                     2 (1.3)                 1
  **Deterioration of pre-existing fungal ball**                                     3 (1.1)                             1 (0.7)                     2 (1.3)                 1
  **All progressive fungal ball**                                                   7 (2.5)                             3 (2.2)                     4 (2.7)                 1
  **Any radiological progression**                                                 34 (11.9)                           15 (11.1)                   19 (12.7)              0.718
  ***Aspergillus* IgG \>20 mg·L^−1^**                             15 (5.3)          28 (9.8)        0.056               9 (6.7)                    19 (12.7)              0.111

Data are presented as n or n (%), unless otherwise stated. ^\#^: present for ≥1 month. All p-values calculated by Fisher\'s exact test. p\<0.05 considered significant.

CT of the thorax was performed in 73 (25.6%) resurvey patients, including 32 out of 46 (69.6%) with chest radiography cavitation in the original survey. CT of the thorax results and accuracy of chest radiography for identification of CT-proven pathology are shown in [table 3](#TB3){ref-type="table"}. Two (0.7%) resurvey patients had a positive GeneXpert test out of 26 samples tested. Neither met diagnostic criteria for CPA.

###### 

Radiology results for the computed tomography (CT) of the thorax group

                               **CT: radiologist 1**   **CT: radiologist 2**   **Final CT result**   **HIV-positive**   **HIV-negative**   **p-value**   **Chest radiography result**   **Sensitivity^\#^ %**   **Specificity^\#^ %**   **PPV^\#^ %**   **NPV^\#^ %**
  --------------------------- ----------------------- ----------------------- --------------------- ------------------ ------------------ ------------- ------------------------------ ----------------------- ----------------------- --------------- ---------------
  **Subjects**                          73                      73                     73                   26                 47                                     73                                                                               
  **Fungal ball**                    12 (16.4)                7 (9.6)               11 (15.1)            3 (11.5)            8 (17)           0.736                9 (12.3)                     36.4                    91.9                44.4            89.1
  **Cavitation**                     41 (56.2)               32 (43.8)              35 (47.9)            9 (34.6)          26 (55.3)          0.142               32 (43.8)                     77.1                    86.8                84.4            80.5
  **Paracavitary fibrosis**          24 (32.9)               30 (41.1)              28 (38.4)            6 (23.1)          22 (46.8)          0.077               20 (27.4)                      50                     86.7                 70             73.6
  **Pleural thickening**             49 (67.1)               64 (87.7)              48 (65.8)           14 (53.8)          34 (72.3)          0.129               31 (42.5)                     60.4                     92                 93.5            54.8
  **Nodule(s)**                      68 (93.2)               58 (79.5)              62 (84.9)           20 (76.9)          42 (89.4)          0.183                                                                                                    
  **Bronchiectasis**                 64 (87.7)               44 (60.3)              54 (74.0)           16 (61.5)          38 (80.9)          0.096                                                                                                    
  **Destroyed lung**                  3 (4.1)                 3 (4.1)                3 (4.1)             1 (3.8)            2 (4.3)             1                                                                                                      

Data are presented as n or n (%), unless otherwise stated. PPV: positive predictive value; NPV: negative predictive value. Nodules, bronchiectasis and destroyed lung were not reported for chest radiography. ^\#^: of chest radiography for identification of CT of the thorax findings. All p-values calculated by Fisher\'s exact test. p\<0.05 considered significant.

Definite CPA was diagnosed in 14 (4.9%) resurvey patients. Full prevalence results are shown in [table 4](#TB4){ref-type="table"}. Two patients had a seronegative fungal ball. Another two who did not undergo CT of the thorax developed probable CPA between surveys, comprising one with a new fungal ball on chest radiography and one with chest radiography cavitation, plus progressive paracavitary fibrosis and pleural thickening and new haemoptysis. In total, 18 (6.3%) resurvey cases had definite or probable CPA. There were an additional eight (2.8%) patients with radiological features of CPA, other than a fungal ball and characteristic symptoms, but negative *Aspergillus*-specific IgG.

###### 

Frequency of chronic pulmonary aspergillosis (CPA)

                                        **All patients**      **HIV-positive**      **HIV-negative**     **p-value**
  ----------------------------------- --------------------- -------------------- ---------------------- -------------
  **Subjects**                                 285                  135                   150           
  **CCPA**                             10 (3.5 (1.8--6.1))   2 (1.5 (0.3--4.7))    8 (5.3 (2.6--9.8))       0.108
  **CFPA**                             3 (1.1 (0.3--2.8))    1 (0.7 (0.1--3.4))    2 (1.3 (0.3--4.2))         1
  **Simple aspergilloma**               1 (0.4 (0--1.6))     1 (0.7 (0.1--3.4))      0 (0 (0--1.7))         0.474
  **All definite CPA**                 14 (4.9 (2.8--7.9))    4 (3.0 (1--6.9))    10 (6.7 (3.5--11.5))      0.177
  **Seronegative fungal ball**         2 (0.7 (0.1--2.2))    1 (0.7 (0.1--3.4))    1 (0.7 (0.1--3.1))         1
  **Probable CPA in non-CT group**     2 (0.7 (0.1--2.2))    2 (1.5 (0.3--4.7))      0 (0 (0--1.7))         0.223
  **All definite and probable CPA**    18 (6.3 (3.9--9.6))   7 (5.2 (2.3--9.9))    11 (7.3 (4--12.3))       0.478

Data are presented as n or n (% (95% CI)), unless otherwise stated. CCPA: chronic cavitary pulmonary aspergillosis; CFPA: chronic fibrosing pulmonary aspergillosis; CT: computed tomography. All p-values calculated by Fisher\'s exact test. p\<0.05 considered significant.

CPA was present in 12 out of 46 (26.1%) resurvey patients with chest radiography cavities and two out of 239 (0.8%) patients with no such cavities (p\<0.001). 12 (85.7%) of the 14 CPA cases had chest radiography cavities, all present in both surveys. Fungal ball was identified in nine (64.3%) CPA cases. Two (14.3%) CPA cases without a fungal ball had destroyed lung and one (7.1%) had progressive cavitation. Two (14.3%) CPA cases met radiological case criteria for CPA due to paracavitary fibrosis alone. Both also had pleural thickening ([figure 2](#F2){ref-type="fig"}). Eight (57.1%) CPA cases had progressive chest radiography changes.

![Radiological presentations of chronic pulmonary aspergillosis (CPA) in Gulu. a) Chronic cavitary pulmonary aspergillosis (CCPA) with multiple cavities and a fungal ball. b) CCPA with a large cavity, paracavitary fibrosis and adjacent pleural thickening, but no fungal ball. c) Chronic fibrosing pulmonary aspergillosis with complete destruction of the whole right lung with multiple cavities and surrounding fibrosis.](ERJ-01184-2018.02){#F2}

All eight resurvey patients with probable CPA in the original survey met CT of the thorax criteria for CPA on resurvey.

Seven (2.5%) resurvey patients developed CPA between surveys, comprising five (1.8%) diagnosed by CT of the thorax and two (0.7%) diagnosed only by chest radiography criteria. Six (86%) of the new CPA cases had chest radiography cavitation on initial survey. The annual rate of CPA development was 1.25% in all patients, 6.5% in the 46 resurvey patients who had chest radiography cavitation on initial survey and 0.2% in the 239 resurvey patients who did not (p\<0.001). The incidence of new CPA was similar in all "time from TB therapy" groups. Five (71.4%) of those who developed new CPA did so within 5 years of completion of TB therapy. Chest radiography progression in a new case of CPA is shown in [figure 3](#F3){ref-type="fig"}.

![Chronic pulmonary aspergillosis (CPA) developing between surveys. a) Chest radiograph from December 2012 shows residual scarring at the left apex and a nodule at the left base in an HIV co-infected patient. b) Second radiograph from December 2014 shows a new cavity with a possible fungal ball at the left apex and evolution of the nodule into small thin-walled cavities at the left base, one probably with a small fungal ball. The patient also developed newly raised *Aspergillus*-specific IgG on resurvey. Computed tomography of the thorax was not performed as the patient had normal *Aspergillus*-specific IgG and no fungal ball on initial survey.](ERJ-01184-2018.03){#F3}

No associations were found between CPA diagnosis and potential clinical and radiological risk factors ([supplementary table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01184-2018.figures-only#fig-data-supplementary-materials)). Associations between individual symptoms and raised *Aspergillus-*specific IgG or CPA are shown in [table 5](#TB5){ref-type="table"}. Cough and haemoptysis were significantly more common in those with raised *Aspergillus-*specific IgG, but other symptoms were not.

###### 

Associations between *Aspergillus* and clinical and radiological findings

                                       **All patients**   ***Aspergillus*-specific IgG-positive**   ***Aspergillus*-specific IgG-negative**   **p-value**     **OR (95% CI)**     **CPA present**   **CPA absent**   **p-value**     **OR (95% CI)**
  ----------------------------------- ------------------ ----------------------------------------- ----------------------------------------- ------------- --------------------- ----------------- ---------------- ------------- ----------------------
  **Symptoms**                              n=285                          n=28                                      n=257                                                             n=14             n=271                     
   Cough^\#^                              94 (33.0)                      15 (53.6)                                 79 (30.7)                     0.015       2.60 (1.18--5.72)       11 (78.6)        83 (30.6)        \<0.001      8.30 (2.26--30.55)
   Haemoptysis^\#^                         21 (7.4)                      8 (28.6)                                  13 (5.1)                     \<0.001     7.51 (2.78--20.24)       7 (50.0)          14 (5.2)        \<0.001     18.36 (5.65--59.60)
   Fatigue                                89 (31.2)                      9 (32.1)                                  80 (31.1)                     0.912       1.05 (0.45--2.42)       6 (42.9)         83 (30.6)         0.336       1.70 (0.57--5.05)
   Fevers                                  26 (9.1)                      3 (10.7)                                  23 (8.9)                      0.729       1.22 (0.34--4.35)       2 (14.3)          24 (8.9)         0.371       1.71 (0.36--8.12)
   Night sweats                           51 (17.9)                      6 (21.4)                                  45 (17.5)                     0.607       1.25 (0.49--3.35)       4 (28.6)         47 (17.3)         0.287       1.91 (0.57--6.34)
   Chest pain                             76 (26.7)                      11 (39.3)                                 65 (25.3)                     0.112       1.91 (0.85--4.29)       7 (50.0)         69 (25.5)         0.06        2.93 (0.99--8.64)
  **Chest radiography (resurvey**)          n=285                          n=28                                      n=257                                                             n=14             n=271                     
   Cavitation                             50 (17.5)                      17 (60.7)                                 33 (12.8)                    \<0.001     10.49 (4.52--23.34)      12 (85.7)        38 (14.0)        \<0.001     36.79 (7.92--170.87)
   Fungal ball                             13 (4.6)                      5 (17.9)                                   8 (3.1)                     \<0.001     6.77 (2.05--22.38)       4 (28.6)          9 (3.3)          0.002       11.64 3.06--44.31
   Paracavitary fibrosis                  36 (12.6)                      7 (25.0)                                  29 (11.3)                     0.038       2.62 (1.02--6.7)        4 (28.6)         32 (11.8)         0.085       2.99 (0.88--10.09)
   Pleural thickening                     50 (17.5)                      16 (57.1)                                 34 (13.2)                    \<0.001     8.74 (3.81--20.07)       10 (71.4)        40 (14.8)        \<0.001     14.44 (4.32--48.28)
  **Chest radiography progression**         n=285                          n=28                                      n=257                                                             n=14             n=271                     
   Cavitation                              7 (2.5)                       4 (14.3)                                   3 (1.2)                      0.002      14.06 (2.97--66.51)       1 (7.1)          6 (2.2)          0.301       3.38 (0.38--30.21)
   Fungal ball                             7 (2.5)                       3 (10.7)                                   4 (1.6)                      0.023      7.56 (1.60--35.70)       2 (14.3)          5 (1.8)          0.041       8.83 (1.55--50.27)
   Paracavitary fibrosis                   18 (6.3)                      5 (17.9)                                  13 (5.1)                      0.008      4.06 (1.33--12.41)       3 (21.4)          15 (5.5)         0.05        4.64 (1.17--18.41)
   Pleural thickening                      16 (5.6)                      5 (17.9)                                  11 (4.3)                      0.003      4.84 (1.55--15.14)       3 (21.4)          13 (4.8)         0.037       5.39 (1.34--21.71)
   Any progressive change                 34 (11.9)                      12 (42.9)                                 22 (8.6)                     \<0.001     8.01 (3.37--19.06)       7 (50.0)         27 (10.0)        \<0.001      9.04 (2.95--27.71)
  **CT of the thorax**                       n=73                          n=21                                      n=52                                                              n=14              n=59                     
   Fungal ball^\#^                        11 (15.1)                      9 (42.9)                                   2 (3.8)                     \<0.001     18.75 (3.58--98.28)      9 (64.3)          2 (3.4)         \<0.001     51.3 (8.61--305.47)
   Cavitation                             35 (47.9)                      16 (76.2)                                 19 (36.5)                     0.002      5.56 (1.76--17.59)       14 (100)         21 (35.6)        \<0.001    
   Paracavitary fibrosis^\#^              28 (38.4)                      16 (76.2)                                 12 (23.1)                    \<0.001     10.67 (3.23--35.19)      14 (100)         14 (23.7)        \<0.001    
   Pleural thickening                     48 (65.8)                      19 (90.5)                                 29 (55.8)                     0.005      7.53 (1.59--35.73)       14 (100)         34 (57.6)         0.003     
   Nodule(s)                              62 (84.9)                      16 (76.2)                                 46 (88.5)                     0.185       0.42 (0.11--1.56)       10 (71.4)        52 (88.1)         0.116       0.337 (0.08--1.37)
   Bronchiectasis                         54 (74.0)                      16 (76.2)                                 38 (73.1)                     0.784       1.17 (0.36--3.82)       12 (85.7)        42 (71.2)         0.265       2.43 (0.49--12.02)
   Destroyed lung                          3 (4.1)                       3 (14.3)                                      0                         0.021                               3 (21.4)             0             0.006     

Data are presented as n (%), unless otherwise stated. CPA: chronic pulmonary aspergillosis; CT: computed tomography. ^\#^: these features formed part of the CPA case definition. All p-values calculated by Fisher\'s exact test. Odds ratios were calculated by bimodal regression analysis. p\<0.05 considered significant.

Fungal ball, cavitation, paracavitary fibrosis and pleural thickening were all significantly more common in those with raised *Aspergillus-*specific IgG, but bronchiectasis and nodules were not. Every patient with destroyed lung had raised *Aspergillus-*specific IgG and CPA. All forms of chest radiography progression were more common in CPA, except progressive cavitation.

The accuracy of combinations of symptoms and tests for CPA diagnosis is shown in [table 6](#TB6){ref-type="table"}. All CPA cases had either cavitation or pleural thickening on chest radiography, but no combination of chest radiography findings and clinical assessment produced a positive predictive value \>40%. Addition of *Aspergillus-*specific IgG measurement allowed CPA diagnosis with a positive predictive value of 92.3% and a negative predictive value of 99.3%.

###### 

Accuracy of test combinations for chronic pulmonary aspergillosis (CPA) diagnosis in the absence of computed tomography of the thorax

  **Test**                                                                              **n**   **Sensitivity %**   **Specificity %**   **PPV %**   **NPV %**
  ------------------------------------------------------------------------------------ ------- ------------------- ------------------- ----------- -----------
  **Serology**                                                                           28            100                94.8            50.0       100^\#^
  **Symptoms**                                                                           101          92.9                67.5            12.9        99.5
  **Serology plus symptoms**                                                             18           92.9                98.2            72.2        99.6
  **Chest radiography fungal ball**                                                      13           28.6                96.7            30.8        96.3
  **Chest radiography cavitation**                                                       50           85.7                86.0            24.0        99.1
  **Chest radiography pleural thickening**                                               50           71.4                85.2            20.0        98.3
  **Chest radiography cavitation or pleural thickening**                                 73            100                78.2            19.2         100
  **Chest radiography cavitation plus symptoms**                                         30           85.7                93.4            40.0        93.4
  **Chest radiography cavitation or pleural thickening plus symptoms**                   41           92.9                89.7            31.7        99.6
  **Serology plus chest radiography cavitation**                                         17           85.7                98.2            70.6        99.3
  **Serology plus chest radiography cavitation plus symptoms**                           13           85.7                99.6            92.3        99.3
  **Serology plus chest radiography cavitation or pleural thickening plus symptoms**     17           92.3                98.5            76.5        99.6

PPV: positive predictive value; NPV: negative predictive value. *^\#^*: positive serology was a mandatory diagnostic criterion for CPA in this study.

Discussion {#s4}
==========

We have performed the first community-based survey of persons with treated pulmonary TB to measure CPA prevalence. It is the first CPA prevalence survey to achieve accurate diagnosis through systematic CT of the thorax and use of an *Aspergillus*-specific IgG assay validated for the study population.

The finding that CPA complicates 4.9--6.3% of all treated pulmonary TB cases and 26% of cases with chest radiography cavitation has profound implications for TB management programmes. It suggests that testing for CPA with *Aspergillus*-specific IgG should be routine in all patients with recurrent cough, haemoptysis or weight loss following treatment of pulmonary TB, regardless of HIV status or time from completion of TB therapy. Those with raised levels should have imaging, preferably with CT of the thorax, to confirm the diagnosis. As CPA mimics the presentation of pulmonary TB, testing should also form part of routine investigations in any patient where empirical treatment for "smear-negative TB" is being considered.

Patients with chest radiography cavities had an annual rate of new CPA of at least 6.5%, a condition associated with 38--80% 5-year mortality. This suggests that all patients should have chest radiography at the end of pulmonary TB treatment and that those with cavities should be monitored for CPA to facilitate early treatment. We identified new cases of CPA occurring up to 9 years after completion of TB therapy. The frequency of new CPA occurring beyond this point is unknown.

We have probably underestimated the frequency of CPA. 10 patients had a combination of symptoms and radiological features suggestive of CPA despite normal *A. fumigatus*-specific IgG, including two with a fungal ball on CT of the thorax. These cases probably represent CPA cases caused by another species, as *A. fumigatus*-specific IgG may have low sensitivity in this group \[[@C17]\]. One patient also had HIV with a CD4 count \<200 cells·µL^−1^. The accuracy of *Aspergillus*-specific IgG in this group is poorly described.

Our study has limitations. Convenience sampling allows recruitment bias, although this was minimised through active recruitment of eligible patients. Our case definition was written prior to the publication of the ERS guidelines \[[@C4]\]. These guidelines require either radiological or symptomatic evidence of disease duration \>3 months for CCPA/CFPA. All our CCPA/CFPA patients met these criteria as 10 out of 13 (77.0%) had symptoms for \>3 months and three had chest radiography evidence of CPA in both surveys. The guidelines also require either a fungal ball on CT of the thorax or the combination of cavitation and radiological progression. 13 out of 14 (93%) CPA cases met these criteria.

Subacute invasive pulmonary aspergillosis typically kills within a few months and is present in 2--11% of AIDS autopsies \[[@C28]--[@C32]\]. We used a 1-month symptom duration definition to allow inclusion of these patients, but we will not have identified patients who developed aspergillosis and died outside the survey periods.

Existing consensus case definitions for CPA are arbitrary and based on expert opinion. We have assessed associations between individual symptoms and raised *Aspergillus*-specific IgG and CPA for the first time. It may be appropriate to restrict future case definitions to cough and haemoptysis. Pleural thickening was present in most CPA cases and was significantly more common in those with CPA or raised *Aspergillus*-specific IgG. It may be appropriate to include CT of the thorax cavitation plus adjacent pleural thickening as radiological evidence of CPA in future case definitions. Progressive cavitation was the only form of chest radiography progression not associated with CPA diagnosis. Every patient with destroyed lung had raised *Aspergillus*-specific IgG and CPA, mandating investigations for CPA in this group.

*Aspergillus* colonisation of bronchiectatic airways is unlikely to be the main cause of raised *Aspergillus*-specific IgG in this population as there was no association between bronchiectasis and raised *Aspergillus*-specific IgG. The absence of any association between nodules and raised *Aspergillus*-specific IgG supports the current recommendation that biopsy is required to diagnose *Aspergillus* nodule disease \[[@C4], [@C33]\].

Prior studies demonstrate the presence of aspergillosis in other post-TB populations. The 1968--1970 study found aspergilloma in 20% of 544 British treated TB patients with residual cavities \[[@C27]\]. New *Aspergillus*-specific antibodies developed in 9.8% and aspergilloma in 5.4% of patients during 2 years of follow-up, indicating an annual rate of aspergilloma development of 2.7%. *Aspergillus*-specific antibodies were found in 8.3% of 350 predominantly treated TB patients in Brazil \[[@C34]\], 23--25% of 77 Indian treated TB patients \[[@C35], [@C36]\], 19% of 226 Japanese patients with active or treated TB \[[@C37]\] and 9% of 101 HIV-positive patients completing pulmonary TB treatment in Kampala \[[@C38]\]. Chest radiography plus serology surveys have found probable CPA in 8.7% of 208 patients completing TB therapy in Nigeria \[[@C22]\] and 11.3% of 124 HIV-negative patents with active or treated TB in Iran \[[@C23]\].

These prior studies are not directly comparable to ours as they took place in select clinical populations, used unvalidated or insensitive serology methods, lacked systematic CT imaging of the thorax and sometimes included non-TB patients in mixed cohorts. Nonetheless, aspergillosis was present at clinically important levels in every population studied and all the studies were consistent with CPA prevalence at least as high as our findings. The combination of our data and these prior studies demonstrates that CPA complicating pulmonary TB represents an unrecognised global public health issue.

Between 2000 and 2016, around 45 million lives were saved due to effective treatment of pulmonary TB worldwide \[[@C1]\]. However, 1.6--3.5 million of these would subsequently have developed CPA if this occurs within the 95% confidence interval identified in our study. Residual chest radiography cavitation is found in 20--30% of the 7.7 million patients cured of pulmonary TB each year \[[@C1]\]. If the annual rates of new CPA we found in those with and without residual cavitation are applied, then 112 000--160 000 people will develop CPA worldwide every year after completion of TB therapy.

This is probably an underestimate as we only diagnosed "new" CPA in those with negative baseline serology. Without baseline CT of the thorax we could not calculate the additional rate of "new" CPA in those with positive baseline serology but no radiological features. This estimate may also be low because it assumes that all patients with pulmonary TB actually had this disease and not CPA, and it omits any patients with both disorders concurrently who died during anti-TB therapy, with undiagnosed CPA.

Fungal ball is absent in most CPA cases \[[@C2]\]. *Aspergillus*-specific IgG and CT of the thorax are therefore required to reliably diagnose CPA cases. Unfortunately, both are rarely available in resource-poor settings \[[@C18]\]. In their absence patients with CPA meet WHO diagnostic criteria for "smear-negative TB" \[[@C39]\]. A recent Nigerian study found probable CPA in 19% of such patients, who were HIV-negative \[[@C22]\]. We found that a fungal ball on chest radiography was insensitive for diagnosing CPA. However, CPA could be excluded by chest radiography in this cohort and diagnosed with acceptable accuracy if *Aspergillus*-specific IgG measurement was also performed.

We therefore propose that CPA should be diagnosed in persons with treated TB in resource-poor settings if recurrent TB has been excluded by GeneXpert PCR testing and a combination of raised *Aspergillus*-specific IgG, chest radiography cavitation and either chronic cough or haemoptysis is present. This proposal requires validation in another population. Improved access to *Aspergillus*-specific IgG is necessary to diagnose CPA in resource-poor settings. Implementation of point-of-care tests, optimised for resource-poor settings, would facilitate this. A lateral flow device for *Aspergillus-*specific IgG has recently been commercialised in Europe (LDBio, Lyon, France).

Untreated CPA is usually fatal, but treatment is possible with relatively inexpensive oral generic antifungals, now included on the WHO Essential Medicine List \[[@C40]\], or surgery in selected cases. Meaningful improvements in TB-associated mortality are therefore possible by addressing CPA in a programmatic way within existing TB care systems. Public health bodies should now act to ensure equitable access to CPA diagnosis and treatment.
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